A phase Ia, dose-finding study to assess the safety and immunogenicity of an Orf virus-based COVID-19 vaccine booster (Prime-2-CoV_Beta) in healthy adults

Status

Suspended

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511266-36-00

Acronym

PRiME2_21_1

Enrollment

Registered

2024-03-26

Start date

2022-06-24

Completion date

Unknown

Last updated

2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The clinical trial itself does not investigate a medical condition or disease. Rather, the safety and immunogenicity of a vaccine against SARS-CoV-2 infection is being investigated.

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Countries

Germany

Outcome results